Save 35% on brand Brukinsa from Insulinhub.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine.
Manufactured in Europe by one of three factories:
BeiGene Switzerland GmbH – Dutch Branch
Evert van de Beekstraat 1, 104
1118 CL Schiphol
The Netherlands
BeiGene Germany GmbH
Georges-Köhler-Str. 2
79539 Lörrach,
Germany
BeiGene Netherlands B.V.
Evert van de Beekstraat 1, 104
1118 CL Schiphol
The Netherlands
Information about Brukinsa (Zanubrutinib)
Brukinsa (generic name: zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor developed by BeiGene. It is mainly used to treat specific types of blood cancers, such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). Zanubrutinib works by inhibiting BTK, a protein that plays a crucial role in the survival and proliferation of cancerous B cells. By targeting this pathway, Brukinsa can reduce the growth of abnormal cells and help manage the disease.
Product Highlights
- Brukinsa is approved for the treatment of the following conditions:
- Mantle Cell Lymphoma (MCL):
For adult patients who have received at least one prior therapy. - Chronic Lymphocytic Leukemia (CLL):
For treatment of adult patients with CLL or small lymphocytic lymphoma (SLL), both of which are types of blood cancers that affect B lymphocytes. - Small Lymphocytic Lymphoma (SLL):
For patients with SLL, a variant of CLL that primarily involves the lymph nodes.
Key Ingredient
Key Benefits
- Zanubrutinib is a selective, potent inhibitor of BTK, which reduces off-target effects and improves the safety profile compared to other BTK inhibitors.
- Brukinsa is taken orally in the form of a capsule, making it more convenient for patients compared to intravenous therapies.
- Brukinsa has shown significant clinical benefits in treating relapsed or refractory MCL, CLL, and SLL, leading to its FDA approval for these indications.
- Compared to first-generation BTK inhibitors, Brukinsa tends to have a more favorable side effect profile, potentially leading to better patient compliance.
Direction of Use
- Dosing for MCL:
- The recommended dose for mantle cell lymphoma is 160 mg orally twice daily (BID).
- Dosing for CLL/SLL:
- The recommended dose for chronic lymphocytic leukemia or small lymphocytic lymphoma is 320 mg orally once daily (QD).
- The dosage may be adjusted based on specific patient conditions, including tolerability and response. It’s important for patients to follow the instructions provided by their healthcare providers for optimal results.
Safety Concerns
- As with other BTK inhibitors, Brukinsa may increase the risk of bleeding, including serious or life-threatening bleeding events. Care should be taken in patients with a history of bleeding disorders or those on anticoagulant therapy.
- Zanubrutinib can increase the risk of infections, including serious bacterial, fungal, and viral infections.
- There may be risks of atrial fibrillation or other arrhythmias. Patients with pre-existing heart conditions should be monitored closely.
- Liver function should be regularly monitored, as abnormal liver enzyme levels have been reported in some patients.
- In rare cases, especially during the initial stages of treatment, patients may develop tumor lysis syndrome (TLS), a potentially life-threatening condition.
Avoid Brukinsa (Zanubrutinib) If
- Patients who have a known hypersensitivity to zanubrutinib or any of its components should not take Brukinsa.
- It should be avoided in patients with a history of or current bleeding disorders that cannot be controlled.
- Those with severe liver problems should avoid this medication, or it should be used with caution and close monitoring.
- Zanubrutinib should not be used during pregnancy unless clearly necessary, as it may harm the fetus. Women of childbearing age should use effective contraception while on this medication.
- Patients with uncontrolled or significant cardiovascular disease, such as recent heart attack or stroke, may need to avoid Brukinsa, or it should be used with caution.
